MONTREAL, Oct. 2 /CNW Telbec/ - Aegera Therapeutics announced today the
initiation of four new clinical oncology studies for AEG35156, a second
generation anti-sense therapeutic targeting the X-Linked Inhibitor of
Apoptosis (XIAP), a key member of the Inhibitor of Apoptosis protein (IAP)
family.
